Considering the mechanism of action of the MKT-077 and its derivatives, it was suggested that they would prove to be effective in the treatment of neuroblastoma, teratocarcinoma, and breast carcinoma, where p53 is inactivated largely by cytoplasmic sequestration. Here, TP53 is linked to breast carcinoma.